Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. It develops when B-lymphocytes become abnormal. It is a mature B-cell neoplasm arising from the germinal center and post germinal center B-cells.
Diffuse Large B-Cell Lymphoma Epidemiology Insights
- The total incident cases of DLBCL in 7MM in 2017 was 67,743
-
DLBCL, NOS cases in the United States in 2017 – 24,933
-
The age-group with the highest incidence of DLBCL among 7MM in 2017 was 65–74 years
-
Males have higher incident cases of DLBCL as compared to females
- The incident population of DLBCL in 2017
- Germany- 7,443
- Japan- 9,485
- The United States – 28,659
Diffuse Large B-Cell Lymphoma Epidemiology Segmentation in 7MM from 2017 to 2030
- Total Incident Cases Of Diffuse Large B-Cell Lymphoma
- Gender-Specific Cases Of Diffuse Large B-Cell Lymphoma
- Age-Specific Cases Of Diffuse Large B-Cell Lymphoma
- Type-Specific Cases Of Diffuse Large B-Cell Lymphoma
- Stage-Specific Cases Of Diffuse Large B-Cell Lymphoma
Scope of the Report
- The Diffuse Large B-cell Lymphoma report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Diffuse Large B-cell Lymphoma Epidemiology Report and Model provide an overview of the risk factors and global trends of Diffuse Large B-cell Lymphoma in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight about the historical and forecasted patient pool of Diffuse Large B-cell Lymphoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Diffuse Large B-cell Lymphoma
- The report provides the segmentation of the Diffuse Large B-cell Lymphoma epidemiology
Request for sample pages
Table of contents
1. Key Insights
2. Executive Summary of Diffuse Large B-cell Lymphoma
3. Diffuse Large B-cell Lymphoma: Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Diffuse Large B-cell Lymphoma Treatment and Management
6.2. Diffuse Large B-cell Lymphoma Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/